A recent study found that cryptocurrencies endorsed by celebrities are almost five times more likely to be fraudulent. This highlights the high risk associated with celebrity-backed crypto projects and urges investors to focus on the technical fundamentals rather than star endorsements. The findings serve as a caution for retail investors to prioritize safer investment criteria over hype. Moving forward, investors should conduct thorough research to avoid scams in the crypto space.
The topic of celebrity-endorsed cryptocurrencies is presented here with Pluang's market data for context. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Sep 23, 2026 22:05 WIB: out of 50 priced major cryptocurrencies, 14 rose and 35 fell. Notable movers include BCH (Bitcoin Cash) at Rp6.059.066 with a 7.00% increase and a typical hold time of 68 days, SNX (Synthetix) at Rp4.432 up 5.42% with a 69-day hold time, and CRV (Curve DAO Token) at Rp5.903 down 5.31% with a 61-day hold time. Pluang order activity shows BCH with 63% sell and 37% buy, SNX with 92% sell and 8% buy, and CRV with 60% sell and 40% buy.
Jefferies analysts set a new price target of $435 for General Electric Aerospace, implying a 35% upside from its current price of around $321. GE Aerospace's strong position is supported by a $170 billion commercial services backlog and 80,000 aircra...
BNP Paribas lowered its price target for PepsiCo from $183 to $161 on September 23, 2026, due to ongoing demand challenges in North America. Despite the cut, the firm maintained an Outperform rating, indicating confidence in the stock's potential. Th...
Celldex Therapeutics saw its price target raised from $70 to $88 by Leerink Partners following successful Phase III trial results for its drug barzolvolimab treating chronic spontaneous urticaria (CSU). The trials met all primary endpoints, showing l...
Ero Copper, a major copper producer, shows stock volatility between $16.88 and $40.83 over the past year. Analyst firm CIBC maintained a "Neutral" rating but increased the price target to C$56.00, reflecting optimism about the company's long-term gro...
Cintas Corporation posted robust first-quarter results, surpassing analyst expectations with earnings per share of $1.39 and revenue of $3.01 billion, a 10.9% increase year-over-year. The company's organic revenue growth was 8.9%, reflecting solid bu...
